**OriGene Technologies, Inc.**
9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

# Product datasheet for TL303214

## MOCOS Human shRNA Plasmid Kit (Locus ID 55034)

### Product data:

| | |
|---|---|
| **Product Type:** | shRNA Plasmids |
| **Product Name:** | MOCOS Human shRNA Plasmid Kit (Locus ID 55034) |
| **Locus ID:** | 55034 |
| **Synonyms:** | HMCS; MCS; MOS |
| **Vector:** | pGFP-C-shLenti (TR30023) |
| **E. coli Selection:** | Chloramphenicol (34 ug/ml) |
| **Mammalian Cell Selection:** | Puromycin |
| **Format:** | Lentiviral plasmids |
| **Components:** | MOCOS - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 55034).<br>5µg purified plasmid DNA per construct<br>29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free. |
| **RefSeq:** | NM_017947, NM_017947.1, NM_017947.2, BC012079, BC012079.1, NM_017947.3 |
| **UniProt ID:** | Q96EN8 |
| **Summary:** | This gene encodes an enzyme that sulfurates the molybdenum cofactor which is required for activation of the xanthine dehydrogenase (XDH) and aldehyde oxidase (AO) enzymes. XDH catalyzes the conversion of hypoxanthine to uric acid via xanthine, as well as the conversion of allopurinol to oxypurinol, and pyrazinamide to 5-hydroxy pyrazinamide. Mutations in this gene cause the metabolic disorder classical xanthinuria type II which is characterized by the loss of XDH/XO and AO enzyme activity, decreased levels of uric acid in the urine, increased levels of xanthine and hypoxanthine in the serum and urine, formation of xanthine stones in the urinary tract, and myositis due to tissue deposition of xanthine. [provided by RefSeq, Apr 2017] |
| **shRNA Design:** | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |

View online »

**Performance Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).